Hepatocellular Carcinoma Tumor Marker Panel
Also known as: HEP CAR
Use
This test is used for the surveillance and monitoring of hepatocellular carcinoma. The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated serum AFP-L3 percent and DCP values are associated with an increased risk for developing hepatocellular carcinoma and patients with such results should be more intensely evaluated for evidence of the disease.
Special Instructions
Results obtained with different assay methods or kits cannot be used interchangeably. For pregnant females, tumor marker results are not interpretable.
Limitations
Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Medication containing vitamin K preparations or antagonists, as well as antibiotics, may bias the DCP values negatively or positively.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 1834-1
- 42332-7
- 34444-0
Result Turnaround Time
3-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection.
Causes for Rejection
Plasma
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 5 days |
| Frozen | 3 months (avoid repeated freeze/thaw cycles) |